Vera Therapeutics, Inc.VERA
ASignal's systematic analysis rates VERA as Neutral.
Reflects the latest available analysis · analyzed Aug 26, 2026
The case on VERA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $499.16M in total cash
- Low debt-to-equity ratio of 0.19x indicating conservative capital structure
- High current and quick ratios suggesting strong liquidity
- Positive price momentum above 20-day moving average
- MACD histogram expanding positively, indicating strengthening short-term trend
- Negative operating and free cash flow trends
- Negative return on equity (-91.75%) and return on assets (-46.76%)
- Current price trading above upper Bollinger Band, suggesting overextension
- RSI at 66.47, approaching overbought territory
- Price below 50-day SMA indicating weakening medium-term trend
See the full verdict on VERA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VERA
Most investors never get a second opinion, let alone several. ASignal runs VERA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.